MedifastFRA:MDF -4.32%68 3-Year ROIIC % is 286.45 as of Dec. 2025, which is 163% above its 10-year median of 108.76. GuruFocus rates FRA:MDF with a GF Score™ of 68/100 and a GF Value™ of €6.99 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 90 Personal Services companies, Medifast ranks better than 94.44% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medifast's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 286.45%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medifast's 3-Year ROIIC % or its related term are showing as below:
FRA:MDF's 3-Year ROIIC % is ranked better than 94.44% of 90
companies
in the Personal Services industry
Industry Median: 7.14
vs FRA:MDF: 286.45
Medifast (FRA:MDF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medifast 3-Year ROIIC % Related Terms
Medifast 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medifast's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MDF vs RGS, EVTK, DROR: 3-Year ROIIC % Comparison
For the Personal Services subindustry, Medifast's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medifast 3-Year ROIIC % vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, Medifast's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medifast's 3-Year ROIIC % falls into.
Medifast's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -12.138 (Dec. 2025) - 136.07646 (Dec. 2022) )
/
( 43.791 (Dec. 2025) - 100.595 (Dec. 2022) )
=
-148.21446
/
-56.804
=
260.92%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medifast (FRA:MDF) has a 3-Year ROIIC % of 286.45 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medifast and its competitors. This is 163% above median its historical median of 108.76. According to the industry distribution chart, Medifast ranks #5 out of 90 companies in the Personal Services industry, placing it in the top 5.6%.
Is Medifast's 3-Year ROIIC % too high?
Medifast's current 3-Year ROIIC % of 286.45 is 163% above median its 10-year median of 108.76. The Personal Services industry median 3-Year ROIIC % is 7.14. Medifast's value of 286.45 is 3911.9% above this industry median. Based on the distribution chart, Medifast ranks #5 out of 90 companies in the Personal Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medifast has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medifast's 3-Year ROIIC % compare to RGS and EVTK?
According to the Personal Services industry distribution chart, Medifast ranks #5 out of 90 companies for 3-Year ROIIC %. This places Medifast in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 7.14. Medifast's value of 286.45 is 3911.9% above this benchmark. While the company's 10-year median is 108.76 vs. the industry median of 7.14, Medifast has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Personal Services company?
The median 3-Year ROIIC % among Personal Services companies is 7.14, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medifast's current 3-Year ROIIC % of 286.45 is 3911.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medifast and its competitors. For the Personal Services industry, the median 3-Year ROIIC % is 7.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medifast's current 3-Year ROIIC % is 286.45, which is 163% above median its own 10-year median of 108.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Based on GuruFocus' analysis, Medifast (FRA:MDF) is currently considered Modestly Overvalued. The stock's GF Value™ is €6.99, compared to a current price of €9.08 — trading 29.9% above its estimated fair value. The current 3-Year ROIIC % is 286.45, which is 163% above median its 10-year median of 108.76 and 3911.9% above the Personal Services industry median of 7.14. Medifast's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medifast (FRA:MDF), the current 3-Year ROIIC % is 286.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medifast (FRA:MDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medifast stock appears to be overvalued.
The current stock price of €9.08 is trading 29.9% above its estimated GF Value™ of €6.99.
GuruFocus considers Medifast to be Modestly Overvalued.
Key valuation signals for FRA:MDF:
3-Year ROIIC %: 286.45 (163% above median its 10-year median of 108.76)
GF Value™: €6.99 vs. price of €9.08 (29.9% above fair value)
Industry Position: 3911.9% above the Personal Services median (#5 of 90)
No single metric tells the full story. See the FRA:MDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
68GF Score
Get the complete analysis for FRA:MDF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MDF has been successfully added to your 
